Optimising HER2 Low and Ultralow IHC Scoring

In this series of webinars, we aim to improve the pathologist’s assessment of HER2 immunohistochemical testing for low-level expression in unresectable or metastatic breast cancer.

 

Acknowledgments:

The RCPAQAP would like to acknowledge Prof Gelareh Farshid (SA Pathology), A/Prof Nirmala Pathmanathan (Westmead Hospital), A/Prof Ben Dessauvagie (Clinipath Pathology), Prof Beena Kumar (Monash Pathology), A/Prof Hema Mahajan (Westmead Hospital), Dr Cameron Snell (Peter MacCallum Cancer Centre), Dr Jane Armes (Sullivan Nicolaides Pathology) Science to Life and Studio 3 Eleven.

Sponsor:

 

 

Webinar: Welcome

2 minutes

Webinar: Clinical Context & Background Requirements for Testing

37 minutes

Webinar: The Australian HER2 Low Focused IHC Scoring Guidelines

21 minutes

Webinar: Illustrative Practice Cases

12 minutes

Webinar: Guided Case Reviews

25 minutes

Webinar: HER2 Reporting in 2024

9 minutes

Webinar: Communicating Results & Guidance for MDTs, Logistics

33 minutes

Webinar: Breast cancer with Ultralow or Null HER2 IHC Expression Clinical Context

44 minutes

Webinar: Breast Cancer with Ultralow or Null HER2 IHC Expression Case Studies

15 minutes